GDF15 (growth differentiation factor 15; HGNC:30142, NCBI Gene ID 9518) is a human locus mapped to chromosome band 19p13.11 that encodes distant TGF-beta superfamily cystine-knot homodimer GDF15 (112 mature aa per monomer; 25 kDa dimer). GDF15 acts in integrated stress response (ATF4/CHOP) & p53 induction -> hindbrain GFRAL-RET receptor anorexia/emesis & sympathetic lipolysis, together with TP53 (Tumor Protein p53 Transcriptional Inducer of GDF15), FGF21 (Companion Mitochondrial Stress Mitokine Gene), and Receptor Tyrosine Kinases (RET Co-Receptor). Encodes the cellular stress-induced mitokine GDF15 that signals through the brainstem GFRAL-RET receptor to regulate appetite, nausea, and energy balance.
Approved Symbol
GDF15
Chromosomal Locus
19p13.11
Encoded Product
Distant TGF-beta superfamily cystine-knot homodimer GDF15 (112 mature aa per monomer; 25 kDa dimer)
Causal driver of hyperemesis gravidarum & cancer cachexia (targeted by ponsegromab); induced by metformin & mitochondrial stress
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 2-exon gene at chromosome 19p13.11 containing p53 (TP53), ATF4/CHOP integrated stress response, and EGR1 binding elements in its promoter, encoding a 308-residue preproprotein cleaved at an RXXR furin site to secrete the mature 25 kDa disulfide-linked dimer.
Cellular & Tissue Expression Profile: Under basal physiological conditions expressed at low levels in liver, kidney, and intestinal epithelium, but synthesized at massive levels by placental syncytiotrophoblasts during pregnancy and induced 10- to 100-fold in hepatocytes, renal tubules, cardiomyocytes, skeletal muscle, and tumors during mitochondrial dysfunction, tissue injury, chemotherapy, or metformin administration.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Unlike canonical TGF-beta ligands that use SMAD receptors, circulating GDF15 acts exclusively on a single specialized receptor complex in the brain: Glial-cell-line-derived neurotrophic factor Family Receptor Alpha-Like (GFRAL), which is expressed strictly in the area postrema and nucleus of the solitary tract (AP/NTS) of the caudal hindbrain and recruits the RET receptor tyrosine kinase to suppress food intake, trigger conditioned nausea/visceral malaise, and stimulate beta-adrenergic lipid mobilization.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Human genetic discoveries proved that elevated fetal/placental GDF15 combined with low pre-pregnancy maternal GDF15 sensitivity (modulated by the coding variant p.His202Asp / H6D) is the primary causal mechanism of nausea and vomiting of pregnancy and severe hyperemesis gravidarum; plasma GDF15 is also the single most strongly up-regulated circulating protein biomarker of chronological aging and mitochondrial myopathy in human proteomics.
Therapeutic & Clinical Pharmacology: Neutralization of circulating GDF15 with the humanized monoclonal antibody ponsegromab (PF-06946860) demonstrated robust restoration of body weight, appetite, and physical activity in Phase 2 clinical trials of patients with cancer cachexia, while metformin-induced GDF15 contributes to metformin weight loss.